Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The Ras Gene02:38

The Ras Gene

6.9K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.1K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

474
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
474
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

386
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
386

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antimicrobial Peptide Fusion and Alginate Encapsulation Broaden the Antibacterial Spectrum and Preserve Storage Stability of the Endolysin <i>Ab</i>Lys1 from <i>Acinetobacter baumannii</i> Phage <i>Ab</i>TZA1.

ACS omega·2026
Same author

Identification of Quinoline Tethered Thiadiazole/Thiazole Derivatives as Potent Tyrosinase Inhibitors With Promising Anti-Toxoplasma gondii Agents: Design, Synthesis, and Computational Analysis.

Drug development research·2026
Same author

ZFHX4 is necessary for dopaminergic neuron differentiation and controls cell cycle by regulating LIN28A.

Stem cell reports·2026
Same author

High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study.

Protein expression and purification·2026
Same author

Investigation of Potent Anti-<i>Mycobacterium tuberculosis</i> Agents Derived from Pyridine Derivatives Targeting the Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Computational Analysis.

Drug design, development and therapy·2026
Same author

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants.

Cancer discovery·2026

Related Experiment Video

Updated: Dec 30, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

PDE6D Inhibitors with a New Design Principle Selectively Block K-Ras Activity.

Farid A Siddiqui1, Catharina Alam1, Petja Rosenqvist2

  • 1Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

ACS Omega
|January 21, 2020
PubMed
Summary
This summary is machine-generated.

Researchers developed novel PDE6D inhibitors with a "chemical spring" to prevent ejection and improve cell penetration, selectively targeting K-Ras for cancer therapy. These compounds show promise in blocking cancer cell proliferation and stemness traits.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.4K

Related Experiment Videos

Last Updated: Dec 30, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.4K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Phosphodiesterase 6D (PDE6D) is a trafficking chaperone and surrogate target for K-Ras4B.
  • K-Ras4B unloading from PDE6D is crucial for K-Ras localization and activity.
  • Current PDE6D inhibitors face challenges with ejection and poor cell penetration.

Purpose of the Study:

  • To engineer PDE6D inhibitors with enhanced resilience against ejection.
  • To improve the cell penetration of PDE6D inhibitors.
  • To develop selective K-Ras inhibitors for potential cancer therapies.

Main Methods:

  • Engineered "chemical spring" into prenyl-binding pocket inhibitors of PDE6D.
  • Attached a cell-penetration group to enhance cellular uptake.
  • Tested model compounds (Deltaflexin-1 and -2) for selectivity against K-Ras and H-Ras, antiproliferative activity, and effects on cancer stemness traits.

Main Results:

  • Achieved micromolar in cellulo potencies in the first generation of inhibitors.
  • Deltaflexin-1 and -2 selectively disrupt K-Ras membrane organization, not H-Ras.
  • Demonstrated antiproliferative activity against colorectal and breast cancer cells.
  • Showed ability to block stemness traits in lung and breast cancer cells.

Conclusions:

  • The modular inhibitor redesign strategy enhances resilience against ejection and improves cell penetration.
  • Developed selective K-Ras disrupting compounds with potential therapeutic applications in cancer.
  • Further development of this approach could lead to more potent PDE6D inhibitors for cancer treatment.